Market leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
15 Aug 2023 - Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported results […]
Read morePolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read more